Pfenex, Inc.: Providing Cost Efficient, Safe and Effective Drugs

Biosimilars provide the world access to the same nature of medications, but at a more cheaper cost. Through these therapeutics, millions of lives around the world are given the relief they need without creating a hole in their pockets. The emergence of these drugs also pushes pharmaceutical companies to price their medications competitively.

Pfenex, Inc. is one of the leading biologics companies that provide access to effective, safe and affordable medicines. The company has a highly diversified platform of protein production and bioanalytic technology that allows the company to create several biosimilars. Additionally, they also have the capacity to rapidly identify production strains, which allows the company to take on research and development of vaccines for infectious diseases. Pfenex put in a strong focus on non-glycosylated biosimilars which allow the company to create a robust pipeline of high-quality therapeutics.

The company has several products in its pipeline development. These therapeutics are being developed by the company or through its partnership with other pharmaceutical businesses. Upon the completion of these advancements, the company has forecasted billions of dollars in sales. The PF529, PF708, PF688 ad PF530 are the biosimilars created by the company drawn from the advancements of Neulasta, Betaseron, Forteo and Cimzia, respectively. The PF582 is a biosimilar drawn from Lucentis, which is being developed by the company in partnership with Hospira. There are three other biosimilars being developed by the company through their joint venture with Stridies Arcolab Limited, these are PF444 (Genotrobin),PF694 (Pegasys) and PF690 (Oncaspar).

In addition to the company’s own research and development and its partnership with other pharmaceutical companies, Pfenex, Inc. also receives funding from the government to continue with the research and development of three vaccines: Px563L (rPA based), Px563L (SDI rPA based) and Px 533. The first two are vaccines for Anthrax, while the last one is for Malaria. Pfenex, Inc. is headquartered in San Diego, California and continues to publicly trade on the American Stock Exchange (PFNX).